Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials
Madelain V, Mentre F, Baize S, Anglaret X, Laouenan C, Oestereich L, Nguyen THT, Malvy D, Piorkowski G, Graw F, Guenther S, Raoul H, De Lamballerie X, Guedj J (2020)
Publication Type: Journal article, Review article
Publication year: 2020
Journal
Book Volume: 9
Pages Range: 258-271
Journal Issue: 5
DOI: 10.1002/psp4.12510
Abstract
In 2014, our research network was involved in the evaluation of favipiravir, an anti-influenza polymerase inhibitor, against Ebola virus. In this review, we discuss how mathematical modeling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a nonhuman primate (NHP) model. The data collected in NHPs were finally used to develop a model of Ebola pathogenesis integrating the interactions among the virus, the innate and adaptive immune response, and the action of favipiravir. We conclude the review of this work by discussing how these results are of relevance for future human studies in the context of Ebola virus, but also for other emerging viral diseases for which no therapeutics are available.
Authors with CRIS profile
Involved external institutions
Université de Paris
France (FR)
Institut Pasteur
France (FR)
Institut national de physique nucléaire et de physique des particules (IN2P3)
France (FR)
Bernhard-Nocht-Institut für Tropenmedizin (BNITM) / Bernhard Nocht Institute for Tropical Medicine
Germany (DE)
Aix-Marseille University / Aix-Marseille Université
France (FR)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Laboratoire P4 - Jean Merieux
France (FR)
France (FR)
Institut Pasteur
France (FR)
Institut national de physique nucléaire et de physique des particules (IN2P3)
France (FR)
Bernhard-Nocht-Institut für Tropenmedizin (BNITM) / Bernhard Nocht Institute for Tropical Medicine
Germany (DE)
Aix-Marseille University / Aix-Marseille Université
France (FR)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Laboratoire P4 - Jean Merieux
France (FR)
How to cite
APA:
Madelain, V., Mentre, F., Baize, S., Anglaret, X., Laouenan, C., Oestereich, L.,... Guedj, J. (2020). Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. CPT: Pharmacometrics and Systems Pharmacology, 9(5), 258-271. https://doi.org/10.1002/psp4.12510
MLA:
Madelain, Vincent, et al. "Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials." CPT: Pharmacometrics and Systems Pharmacology 9.5 (2020): 258-271.
BibTeX: Download